A multicenter, prospective, open-label study to evaluate the pharmacokinetics and safety of gadoquatrane in pediatric participants (from birth to <18 years) undergoing contrast-enhanced magnetic resonance imaging (CE-MRI)

Myoishi Masafumi0 个研究点目标入组 100 人开始时间: 2023年7月28日最近更新: 2024年5月27日

试验速览

阶段: 3 期
状态: 招募中
发起方
入组人数: 100

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: ot applicable 至 < 18age old（—）
性别: All

入选标准

•Participants from birth to <18 years of age at the time of signing the informed consent form.
•- Participants who have a clinical indication to undergo a CE-MRI for any clinical condition in any body region and who can undergo study procedures as per Investigator judgement.
•- Participants can be male or female (according to their reproductive organs and functions assigned by chromosomal complement).
•- Female contraception and barriers as well as pregnancy testing is required as appropriate for the age and sexual activity of pediatric participants and as required by local regulations.
•- The legal guardian(s) is capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
•- When applicable by law for a participant, a legal guardian must be available to help the study-site personnel ensure follow up, accompany the participant to the study site on each assessment day, and consistently and consecutively be available to provide information on the participant during the scheduled study visits.

排除标准

•- Body weight <2500 g at screening and baseline
•- The medical condition and/or local allowance for maximum blood draw in the pediatric participant is not suitable for study procedures, including pharmacokinetics (PK) and safety blood draws, without compromising any expected clinical care/procedure need.
•- Acute kidney injury (i.e., acute renal failure).
•- Age-adjusted renal function is decreased (eGFR <80% of age adjusted normal renal function) as evaluated by the investigator based on a serum creatinine result obtained within 2 weeks prior to study intervention.
•- Considered clinically unstable or has a concurrent/concomitant condition that may not allow participation for the full planned study period, in the judgement of the investigator.
•- History of moderate to severe allergic-like reaction to any GBCA.
•- Bronchial asthma considered unstable or had major therapeutical modification within last 4 weeks.
•- Severe cardiovascular disease, except for cardiac or vascular magnetic resonance (MR), if considered clinically justified by the investigator.
•- Planned or expected intervention (e.g., treatment or procedure) or change in treatment (e.g. start of chemotherapy) that may significantly affect study parameters (i.e. safety/adverse events [AEs] [e.g. confounding AEs or safety events due to surgery or chemotherapy], PK parameters) or would prevent the participant from performing study procedures, from the administration of gadoquatrane up to the 24 h +- 4 h follow-up.
•- Participants who received or will receive any other contrast agent within 72 hours prior to gadoquatrane injection or up to 72 hours after gadoquatrane injection.
•- Contraindications to the administration of GBCAs (depending on local product label), or history of adverse reaction to GBCAs.

研究者

发起方

Myoishi Masafumi

相似试验

已完成

3 期

Evaluation of DEAT0217 versus standard of care to compare effectiveness and safety in treating moderate psoriasis in adult patientsAdult patients diagnosed with mild to moderate psoriasis.Skin and Connective Tissue Diseases

ISRCTN28479470Devintec SAG42

尚未招募

4 期

Comparison of personalised coaching program with standard of care in Type 2 diabetes management

CTRI/2024/05/068043Ragus Healthcare Private Limited

已完成

4 期

A multicenter, randomised, open-label study to evaluate the clinical efficacy and pharmacokinetics of oral tacrolimus (FK506) therapy under fasting and fed conditions in refractory ulcerative colitisulcerative colitis

JPRN-UMIN000003952Department of lower gastroenterology, Hyogo College of Medicine40

招募中

不适用

Clinical Evaluation of Low Cost Single use Safety syringe

CTRI/2017/06/008864Indian Council of Medical Research ICMR

进行中（未招募）

不适用

An non-blinded, mulicenter study to investigate the mechanisms which are involved in the interaction of red blood cells with the study drug IgPro10 in patients with chronic immune thrombocytopenic purpura (ITP) who have shown signs of hemolysis (a breakdown or destruction of red blood cells).Chronic immune thrombocytopenic purpura (ITP)MedDRA version: 16.0Level: PTClassification code 10021245Term: Idiopathic thrombocytopenic purpuraSystem Organ Class: 10005329 - Blood and lymphatic system disorders

EUCTR2011-000263-27-BGCSL Behring GmbH150